BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 2878130)

  • 1. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
    Rees JK; Gray RG; Swirsky D; Hayhoe FG
    Lancet; 1986 Nov; 2(8518):1236-41. PubMed ID: 2878130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
    Rees JK; Gray RG; Wheatley K
    Br J Haematol; 1996 Jul; 94(1):89-98. PubMed ID: 8757514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
    Hann IM; Stevens RF; Goldstone AH; Rees JK; Wheatley K; Gray RG; Burnett AK
    Blood; 1997 Apr; 89(7):2311-8. PubMed ID: 9116274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
    Hann I; Vora A; Richards S; Hill F; Gibson B; Lilleyman J; Kinsey S; Mitchell C; Eden OB
    Leukemia; 2000 Mar; 14(3):356-63. PubMed ID: 10720126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
    Stevens RF; Hann IM; Wheatley K; Gray RG
    Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
    Goldstone AH; Burnett AK; Wheatley K; Smith AG; Hutchinson RM; Clark RE;
    Blood; 2001 Sep; 98(5):1302-11. PubMed ID: 11520775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
    Champlin R; Jacobs A; Gale RP; Boccia R; Elashoff R; Foon K; Zighelboim J
    Lancet; 1984 Apr; 1(8382):894-6. PubMed ID: 6200742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAD-induction therapy for 175 adults with acute myeloid leukemia, followed by consolidation and maintenance therapy. The joint study of Ulm and Tübingen.
    Link H; Kurrle E; Frauer HM; Heil G; Heimpel H; Waller HD; Ostendorf P; Wilms K; Hoelzer D
    Onkologie; 1986 Jun; 9(3):135-8. PubMed ID: 3528958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
    Evensen SA; Brinch L; Stavem P; Tjønnfjord G
    J Intern Med; 1992 Nov; 232(5):433-7. PubMed ID: 1453128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
    Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
    N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
    Burnett AK; Hills RK; Milligan DW; Goldstone AH; Prentice AG; McMullin MF; Duncombe A; Gibson B; Wheatley K
    J Clin Oncol; 2010 Feb; 28(4):586-95. PubMed ID: 20038732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.